Acceleron Pharma (XLRN) Stock Pops 23.33% Within The Week: Here What You Should Know About It

Today on the agenda, the stock market of healthcare company experiences a surge in prices. The value has reached a new price mark of $175. Comparing the monthly statistics, it could be noticed that the company showed positive dynamics. Prices were fluctuating from $129.77 to $175.00. Acceleron Pharma (XLRN) continues to increase, the statistics show a rapid surge in prices. Acceleron Pharma, a mid-cap hematological and pulmonary pharmaceutical, saw its stock rise 23.33% this week. While the catalyst for the double-digit increase was not immediately apparent, Bloomberg News reported late Friday afternoon that the company is in advanced talks to be acquired for around $11 billion, or $180 per share in an all-cash deal. Although Bristol Myers Squibb is the apparent candidate, Bloomberg was unable to identify the prospective suitor in its original story. Bristol already holds a significant part in Acceleron to its acquisition of Celgene, and the two firms are working together on the blood cancer medication Reblozyl and the late-stage PAH treatment candidate Sotatercept.

Miriam Bozini

Finance and Business Reporter